Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586515 · ClinicalTrials.gov registry record · Phase 1
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 630
- Enrollment target
- 20
- Study locations
NCT06586515: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Eli Lilly and Company.
NCT06586515 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 630 participants, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06586515, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 630 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Primary Outcome
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Cetuximab
- DRUG Gemcitabine
- DRUG nab-paclitaxel
- DRUG LY3962673
Study Locations (20)
Tennessee
- Sarah Cannon Research Institute - Nashville
- USO - US Oncology Research Network - Nashville
- Vanderbilt University School of Medicine - Nashville
California
- City of Hope - Duarte
- University of California, Los Angeles (UCLA) - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
New York
- New York University (NYU) Langone Medical Center - New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
Ohio
- University of Cincinnati (UC) - Cancer Institute - Cincinnati
- Cleveland Clinic - Cleveland
Colorado
- Sarah Cannon Research Institute at HealthOne - Denver
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2024-09-12 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What NCT06586515 shows while recruiting
NCT06586515 is an interventional study that assigns participants to a tested intervention. The registered 630 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT06586515 names 20 study sites across 13 states, led by Tennessee, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06586515 about?
NCT06586515 is a clinical study titled "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors". The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
What is the current status of trial NCT06586515?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 630 participants. The study started on 2024-09-12. Estimated completion is 2029-03.
What conditions does trial NCT06586515 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06586515?
The interventions under investigation include: Oxaliplatin (DRUG), Cetuximab (DRUG), Gemcitabine (DRUG), nab-paclitaxel (DRUG), LY3962673 (DRUG).
Who is sponsoring clinical trial NCT06586515?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586515 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06586515's enrollment target sits among peer trials
630 50th of 454 higher than 403 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
- NCT06053762 · 630 participants · NA
Identify the Usefulness of Peer-facilitated Versus Self-navigated Quit Tobacco Program for Youths.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI